NervGen Restates Q2 Results to CAD 10.8 Million Net Income From Net Loss
NervGen Pharma restated financial statements to correct material stock-option and warrant-derivative valuation errors, as well as misclassified share issuance costs. Net income for the six months ended June 30, 2026, was corrected to CAD 8.88 million from a CAD 30.89 million loss. Warrant derivative liabilities at June